Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.

Mir O, Coriat R, Dhooge M, Perkins G, Boudou-Rouquette P, Brezault C, Ropert S, Durand JP, Chaussade S, Goldwasser F.

Anticancer Drugs. 2012 Aug;23(7):739-44. doi: 10.1097/CAD.0b013e3283556b9b.

PMID:
22700002
2.

Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.

Mir O, Coriat R, Boudou-Rouquette P, Ropert S, Durand JP, Cessot A, Mallet V, Sogni P, Chaussade S, Pol S, Goldwasser F.

Med Oncol. 2012 Dec;29(4):2793-9. doi: 10.1007/s12032-012-0208-x. Epub 2012 Mar 17.

PMID:
22427209
3.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
4.

FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.

Novarino AM, Satolli MA, Chiappino I, Giacobino A, Napoletano R, Ceccarelli M, Ciccone G, Schena M, Bertetto O, Ciuffreda L.

Am J Clin Oncol. 2013 Oct;36(5):466-71. doi: 10.1097/COC.0b013e31825691c3.

PMID:
22781390
5.

Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.

Hollebecque A, Bouché O, Romano O, Scaglia E, Cattan S, Zerbib P, Heurgue A, Lagarde S, Mariette C, Triboulet JP, Pruvot FR, Hebbar M.

Chemotherapy. 2010;56(3):234-8. doi: 10.1159/000316848. Epub 2010 Jun 16.

PMID:
20551640
6.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K.

Cancer. 2006 Mar 15;106(6):1339-46.

7.

Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.

Dhooge M, Coriat R, Mir O, Perkins G, Brezault C, Boudou-Rouquette P, Goldwasser F, Chaussade S.

Oncology. 2013;84(1):32-8. doi: 10.1159/000342763. Epub 2012 Oct 16.

PMID:
23076239
8.

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.

Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O, Henss H.

Br J Cancer. 2006 Oct 9;95(7):848-52. Epub 2006 Sep 12.

9.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W.

Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628.

10.

Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis.

Wu CE, Hsu HC, Shen WC, Lin YC, Wang HM, Chang JW, Chen JS.

Chang Gung Med J. 2012 Sep-Oct;35(5):420-7.

PMID:
23127347
11.

Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.

Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ.

Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7. doi: 10.1007/s00280-009-1069-7. Epub 2009 Aug 4.

PMID:
19652971
12.

Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.

Yang R, Wang B, Chen YJ, Li HB, Hu JB, Zou SQ.

Anticancer Drugs. 2013 Sep;24(8):871-7. doi: 10.1097/CAD.0b013e3283637292. Review.

PMID:
23799294
13.

A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.

Halim A, Ebrahim MA, Saleh Y.

Jpn J Clin Oncol. 2011 Feb;41(2):217-24. doi: 10.1093/jjco/hyq207. Epub 2010 Nov 8.

PMID:
21062755
14.

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.

Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.

BMC Cancer. 2008 Dec 18;8:374. doi: 10.1186/1471-2407-8-374.

15.

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.

von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F.

BMC Cancer. 2005 Jun 12;5:61.

16.

A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.

Kameda R, Ando T, Kobayashi S, Ueno M, Ohkawa S.

Jpn J Clin Oncol. 2013 Jun;43(6):636-40. doi: 10.1093/jjco/hyt059. Epub 2013 Apr 25.

PMID:
23619988
17.

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C; GERCOR Group..

Ann Oncol. 2004 Sep;15(9):1339-43.

PMID:
15319238
18.

Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.

Cassier PA, Thevenet C, Walter T, Baulieux J, Scoazec JY, Bancel B, Adham M, Souquet JC, Ponchon T, Lombard-Bohas C.

Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1111-7. doi: 10.1097/MEG.0b013e3283396dde.

PMID:
20386107
19.

Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.

Croitoru A, Gramaticu I, Dinu I, Gheorghe L, Alexandrescu S, Buica F, Luca I, Becheanu G, Herlea V, Simionov I, Hrehoret D, Lupescu I, Popescu I, Diculescu M.

J Gastrointestin Liver Dis. 2012 Sep;21(3):277-84.

20.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.

Milella M, Gelibter AJ, Pino MS, Bossone G, Marolla P, Sperduti I, Cognetti F.

Oncologist. 2010;15(2):e1-4. doi: 10.1634/theoncologist.2008-0135.

Supplemental Content

Support Center